Our present data revealed that the FGF-19 levels were twice as high in breast cancer and tripled in dense breast tissue, compared with the normal tissues within each cohort, suggesting that FGF-19 may be a clinically relevant protein to target also in human breast tissue. The gene discussed is FGF19; the disease is breast carcinoma.